Concurrent urothelial carcinoma in the renal pelvis of an allograft kidney and native recipient bladder: evidence of donor origin. 2014

Ei-ichiro Takaoka, and Jun Miyazaki, and Tomokazu Kimura, and Takahiro Kojima, and Koji Kawai, and Yoshihiko Murata, and Naoe Itoguchi, and Yuko Minami, and Takako Nakamura, and Katsuya Honda, and Hiroyuki Nishiyama
*Department of Urology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba City, Ibaraki 305-8575, Japan. nishiuro@md.tsukuba.ac.jp.

A 44-year-old woman was admitted to the hospital for asymptomatic gross hematuria. At the age of 28, she underwent transplantation of a kidney from her father for end-stage renal disease secondary to rapidly progressive glomerulonephritis. She resumed peritoneal dialysis when the allograft kidney stopped functioning at the age of 42. Dialysis was continued for the next 2 years, when the hematuria occurred and she was readmitted. Radiologic evaluation and transurethral resection of the bladder tumor revealed a tumor of the renal pelvis of the allograft kidney (cT3N0M0) and multiple bladder tumors (cT1N0M0). Total cystectomy and allograft nephroureterectomy were performed. Histopathological examinations revealed high grade urothelial carcinoma in the renal pelvis of the allograft kidney (pT3) and native bladder (pT1). Fluorescence in situ hybridization of both specimens demonstrated that the renal pelvic tumors and bladder cancer possessed XY karyotypes. These results indicated that the urothelial carcinoma developed de novo in the renal pelvis of the allograft kidney and was implanted into the recipient's native bladder.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D007682 Kidney Pelvis The flattened, funnel-shaped expansion connecting the URETER to the KIDNEY CALICES. Renal Pelvis,Pelvis, Kidney,Pelvis, Renal
D008297 Male Males
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D009378 Neoplasms, Multiple Primary Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites. Neoplasms, Synchronous,Neoplasms, Synchronous Multiple Primary,Multiple Primary Neoplasms,Multiple Primary Neoplasms, Synchronous,Synchronous Multiple Primary Neoplasms,Synchronous Neoplasms,Multiple Primary Neoplasm,Neoplasm, Multiple Primary,Neoplasm, Synchronous,Primary Neoplasm, Multiple,Primary Neoplasms, Multiple,Synchronous Neoplasm
D009392 Nephrectomy Excision of kidney. Heminephrectomy,Heminephrectomies,Nephrectomies
D009679 Nuclear Family A family composed of spouses and their children. Daughters,Sons,Daughter,Families, Nuclear,Family, Nuclear,Nuclear Families,Son

Related Publications

Ei-ichiro Takaoka, and Jun Miyazaki, and Tomokazu Kimura, and Takahiro Kojima, and Koji Kawai, and Yoshihiko Murata, and Naoe Itoguchi, and Yuko Minami, and Takako Nakamura, and Katsuya Honda, and Hiroyuki Nishiyama
April 2006, Human pathology,
Ei-ichiro Takaoka, and Jun Miyazaki, and Tomokazu Kimura, and Takahiro Kojima, and Koji Kawai, and Yoshihiko Murata, and Naoe Itoguchi, and Yuko Minami, and Takako Nakamura, and Katsuya Honda, and Hiroyuki Nishiyama
November 2011, Pathology international,
Ei-ichiro Takaoka, and Jun Miyazaki, and Tomokazu Kimura, and Takahiro Kojima, and Koji Kawai, and Yoshihiko Murata, and Naoe Itoguchi, and Yuko Minami, and Takako Nakamura, and Katsuya Honda, and Hiroyuki Nishiyama
January 2010, Pathology,
Ei-ichiro Takaoka, and Jun Miyazaki, and Tomokazu Kimura, and Takahiro Kojima, and Koji Kawai, and Yoshihiko Murata, and Naoe Itoguchi, and Yuko Minami, and Takako Nakamura, and Katsuya Honda, and Hiroyuki Nishiyama
May 2022, IJU case reports,
Ei-ichiro Takaoka, and Jun Miyazaki, and Tomokazu Kimura, and Takahiro Kojima, and Koji Kawai, and Yoshihiko Murata, and Naoe Itoguchi, and Yuko Minami, and Takako Nakamura, and Katsuya Honda, and Hiroyuki Nishiyama
August 2010, The Journal of urology,
Ei-ichiro Takaoka, and Jun Miyazaki, and Tomokazu Kimura, and Takahiro Kojima, and Koji Kawai, and Yoshihiko Murata, and Naoe Itoguchi, and Yuko Minami, and Takako Nakamura, and Katsuya Honda, and Hiroyuki Nishiyama
January 2022, Case reports in nephrology and dialysis,
Ei-ichiro Takaoka, and Jun Miyazaki, and Tomokazu Kimura, and Takahiro Kojima, and Koji Kawai, and Yoshihiko Murata, and Naoe Itoguchi, and Yuko Minami, and Takako Nakamura, and Katsuya Honda, and Hiroyuki Nishiyama
July 2014, Urology annals,
Ei-ichiro Takaoka, and Jun Miyazaki, and Tomokazu Kimura, and Takahiro Kojima, and Koji Kawai, and Yoshihiko Murata, and Naoe Itoguchi, and Yuko Minami, and Takako Nakamura, and Katsuya Honda, and Hiroyuki Nishiyama
June 1989, Transplantation,
Ei-ichiro Takaoka, and Jun Miyazaki, and Tomokazu Kimura, and Takahiro Kojima, and Koji Kawai, and Yoshihiko Murata, and Naoe Itoguchi, and Yuko Minami, and Takako Nakamura, and Katsuya Honda, and Hiroyuki Nishiyama
May 2018, BMJ case reports,
Ei-ichiro Takaoka, and Jun Miyazaki, and Tomokazu Kimura, and Takahiro Kojima, and Koji Kawai, and Yoshihiko Murata, and Naoe Itoguchi, and Yuko Minami, and Takako Nakamura, and Katsuya Honda, and Hiroyuki Nishiyama
January 2016, Journal for immunotherapy of cancer,
Copied contents to your clipboard!